The diagnosis of a haemophilia A carrier over 2 decades

Dubé, Évemie; Gauthier, Julie; Merlen, Clémence; Bonnefoy, Arnaud; Couture, Françoise; Lillicrap, David; Rivard, Georges‐Étienne

doi:10.1111/hae.14073

Cited by 1 publication

(2 citation statements)

References 7 publications

(11 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[22][23][24] Failure to test these variants possibly lead to error and slowness in diagnosis. 25 The MLPA technique The ID assigned to each laboratory in a country has been defined and described in Supplementary Table 1.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Accessibility and visibility of genetic testing for haemophilia across Europe: Where do we stand?

Lannoy¹,

Hermans²

2022

Haemophilia

View full text Add to dashboard Cite

Introduction:Haemophilia is characterized by bleeding complications resulting from clotting factor VIII (FVIII) or IX (FIX) deficiency. Identifying the causal pathogenic genetic variant denotes a vital aspect of haemophilia management.Aim: This study evaluated the accessibility and performances of genetic testing for haemophilia across Europe. The types of genetic analyses, techniques used, turnaround time (TAT) and costs were collected and analysed, as were data updating and quality control.Methods: Reported data were retrieved from open access resources, including international databases, Google, laboratory websites, PubMed and government organizations.Results: Overall, 51 genetic laboratories across 15 European countries providing recently updated molecular haemophilia testing were identified. Gene sequencing for small variants of both F8 and F9 genes was provided in most surveyed laboratories. Almost two-thirds of them offer analysis for inversions using a polymerase chain reaction (PCR) method and detection of copy number variation (CNV) using multiplex ligation-dependent probe amplification (MLPA). Cost and TAT were found to vary considerably. In total, 74% of laboratories exhibited a last modified date or change history. The same percentage of laboratories was in possession of an ISO 15189 standard accreditation, whereas only few of them recently performed external quality assessment schemes (EQA) for haemophilia. Conclusion:Despite several initiatives to improve access to genetic testing for haemophilia, such access must still be improved. Our study similarly revealed the large heterogeneity of the variants tested, techniques employed, TAT, cost and quality among the surveyed laboratories.

show abstract

Section: Resultsmentioning

confidence: 99%

“…Surprisingly, around 27% of laboratories did not indicate searching for CNVs, accounting for 5% and 13% of genetic causes in severe HA and HB phenotypes, respectively 22–24 . Failure to test these variants possibly lead to error and slowness in diagnosis 25 . The MLPA technique was revealed to be by far the most used technique (Tables 3 and 4).…”

mentioning

confidence: 99%

Accessibility and visibility of genetic testing for haemophilia across Europe: Where do we stand?

Lannoy¹,

Hermans²

2022

Haemophilia

View full text Add to dashboard Cite

show abstract

The diagnosis of a haemophilia A carrier over 2 decades

Cited by 1 publication

References 7 publications

Accessibility and visibility of genetic testing for haemophilia across Europe: Where do we stand?

Accessibility and visibility of genetic testing for haemophilia across Europe: Where do we stand?

Contact Info

Product

Resources

About